Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,782.81
(
2.51%
)
US TECH 100
24,180.80
(
2.71%
)
Dow Jones
47,909.92
(
2.85%
)
Brent Oil
94.73
(
-0.12%
)
Bitcoin
71,062.00
(
-0.10%
)
News Focus
News Focus
Post# of 820846
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jondoeuk

Send PM Follow Ignore
Followers 36
Posts 3448
Boards Moderated 1
Alias Born 10/24/2015

jondoeuk

Re: TiltMyBrain post# 441450

Friday, 02/04/2022 3:41:23 PM

Friday, February 04, 2022 3:41:23 PM

Post# of 820846
At the recommended Phase 2 dose of lenzilumab (plus Yescarta), the ORR was 100% and no patient experienced Gr3 (or above) cytokine release syndrome or neurotoxicity. A randomised, multicenter, potentially registrational, PhII trial (n=150) should be underway soon.

Going forward, they may not even need to give that mAb (as they can knockout GM-CSF in the CAR-T cells) https://ashpublications.org/blood/article/133/7/697/260575/GM-CSF-inhibition-reduces-cytokine-release
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News